Published on Tuesday July 07, 2020
Smooth Drug Development June 2020 News Release
Smooth Drug Development were working on the following new projects in June:
- We signed a contract with a Russian company for organization of a clinical trial phase I with INN: Nadroparin calcium
- We signed a contract with our long-term Sponsor for organization of a twenty-eight-day clinical trial phase IV with Product: Admera
- We signed a contract with a leading Indian company for medical writing for a twelve-week clinical trial phase IV with Product: Admera
- We signed a contract for medical writing for clinical trial phase III with INN: Ibuprofen + Pitofenone + Fenpiverinium bromide
- We signed a contract for medical writing for clinical trial phase III with INN: Treprostinil with our CRO partner from Lithuania
- We signed a contract for medical writing for bioequivalence clinical trial with INN: Tiratricol
- Smooth was awarded with an agreement for consulting services (INN: Fulvestrant)
- We signed study agreement for phase III trial with INN: Metamizole sodium+Pitofenone+Fenpiverinium bromide
We are happy to reach the following milestones in our projects. The projects are moving regardless the pandemic situation:
- Nimesulide phase II study data base is locked
- CTA was performed in our phase II study in COVID-19, SIVs are performed
- Last patient last visit was performed in our phase III PID study in children
- CSR in etoricoxib trial was submitted to MoH
- Dysmenorrhoea pain phase III study is initiated
- Clinical part in schizophrenia phase III is close to an end
- Close out visit was performed in Erlotinib trial